The all-in-one platform to find and track your stocks and investments
Discover the features
Statistics
Market Cap
33 million
PE Ratio
-
Beta (volatility)
0.72
Earnings Per Share
-2.03
About
ISIN : SE0005003654
Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer; and Phase Ib/II...
Price
Performance Comparison
| Mendus AB (publ) | |
|---|---|
| 1 year return |
-29 %
|
| 5 years return |
-96 %
|
Valuation
| Price to Book | Payout ratio | PEG Ratio |
|---|---|---|
| 0.57 | 0 % | 0.00 |
| Price to Sales | Price / FCF | E.V.R. |
|---|---|---|
| 6.6 | -3.56 | 338.45 |
Price–Earnings Ratio History
The Price–Earnings Ratio history is not available for this stock.
Dividend History
It looks like no dividends is being distributed for this stock...
Number of Outstanding Shares
Financials
Year-over-Year growth
Profitability
Health
Create a portfolio & add this stock
Add this stock and others to your own virtual portfolio and get personalised information : total annual dividends & total value, sectors breakdown, etc.
Privacy Policy • Terms and Conditions
© Copyright 2020-2026 Epsylia OÜ - All rights reserved
Moning is a platform that does not manage any funds and is purely educational. We do not provide any investment advice.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.